Bio-Techne’s 21% return over the past six months has outpaced the S&P 500 by 10.9%, and its stock price has climbed to $62.36 ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

TECHNE is a practice-based digital arts research initiative founded by Professor Mark Amerika, at the University of Colorado at Boulder. The TECHNE initiative develops innovative approaches to the ...

Management expects growth momentum to slow to low-single digits in Q4 due to uncertainties around NIH funding and tariffs. Adjusted operating margin is projected to be 100 to 150 basis points lower in ...